Clinical Trials

Boehringer Ingelheim has announced the launch of three Phase III clinical trials aimed at advancing precision oncology for patients with some of the most aggressive forms of cancer. The…
Read More...

uniQure has reported encouraging early clinical results from its experimental gene therapy AMT-260, offering new hope for patients living with refractory mesial temporal lobe epilepsy…
Read More...

Massive Bio and Optellum have announced a strategic collaboration designed to connect early lung cancer detection with faster access to clinical trials, potentially addressing one of…
Read More...

SystImmune and Bristol Myers Squibb have reported positive Phase 3 results for izalontamab brengitecan (iza-bren), an investigational bispecific antibody-drug conjugate (ADC),…
Read More...

British pharmaceutical company GSK has reported encouraging late-stage clinical trial results for bepirovirsen, an investigational therapy for chronic hepatitis B (CHB), raising hopes…
Read More...

Regeneron Pharmaceuticals reported encouraging early-stage results from a Phase 1/2 clinical trial evaluating Lynozyfic (linvoseltamab) in patients with relapsed or treatment-resistant…
Read More...

Global pharmaceutical company Merck & Co. has announced positive pivotal Phase 3 results for sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug…
Read More...

AstraZeneca announced positive interim results from the Phase III VOLGA clinical trial, showing that perioperative treatment with Imfinzi combined with neoadjuvant enfortumab vedotin…
Read More...

Madrigal Pharmaceuticals, Inc. has entered into an exclusive global licensing agreement with Arrowhead Pharmaceuticals to develop and commercialize ARO-PNPLA3, a clinical-stage…
Read More...

Akeso, Inc. has announced that its novel trispecific antibody candidate, AK150, has received Investigational New Drug (IND) clearance from the National Medical Products Administration…
Read More...

Vima Therapeutics has announced significant progress in the development of its experimental treatment for movement disorders, revealing that the first patient has been dosed in a Phase…
Read More...

Biotechnology companies Akeso, Inc. and INOVIO have announced a clinical trial collaboration and supply agreement to evaluate a new combination immunotherapy approach for glioblastoma…
Read More...

Novartis has announced positive topline results from its pivotal Phase III RemIND trial evaluating oral remibrutinib in patients with chronic inducible urticaria (CIndU), a condition…
Read More...

Johnson & Johnson has unveiled new data from its Phase 1b/2 OrigAMI-4 study, demonstrating that first-line treatment with investigational subcutaneous amivantamab and…
Read More...

IQVIA, a global provider of clinical research services, healthcare intelligence, and commercial insights, has entered into a strategic long-term collaboration with Boehringer Ingelheim…
Read More...

GSK plc has reported positive results from two pivotal phase III clinical trials evaluating bepirovirsen, an investigational antisense oligonucleotide therapy for chronic hepatitis B…
Read More...

Takeda Pharmaceutical Company has announced it will discontinue its cell therapy research and development efforts as part of a broader strategic portfolio prioritization. The company…
Read More...

Harmony Biosciences Holdings, Inc. has released topline results from its Phase 3 RECONNECT Study evaluating ZYN002, a transdermal cannabidiol gel, in patients with Fragile X syndrome…
Read More...

Cellectar Biosciences, a late-stage clinical biopharmaceutical company specializing in cancer drug development, has entered into an agreement with Evestia Clinical to provide full…
Read More...

The New England Journal of Medicine has published the results from Novo Nordisk’s OASIS 4 Phase 3 trial, marking a major advance in obesity treatment with the investigational once-daily…
Read More...